var data={"title":"Pyrimethamine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pyrimethamine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6880?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pyrimethamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pyrimethamine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pyrimethamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pyrimethamine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216093\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Daraprim</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216094\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Daraprim [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216127\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antimalarial Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216098\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Isosporiasis (</b>\n      <b>\n        <i>Isospora belli </i></b> <b>infection) in HIV-infected patients (alternative agent)</b> <b>(off-label use) (HHS [OI adult 2015]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i> 50 to 75 mg once daily in combination with leucovorin calcium</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic maintenance (secondary prophylaxis):</i> 25 mg once daily in combination with leucovorin calcium</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Pneumocystis </i></b> <b>pneumonia (PCP) in HIV-infected patients (alternative agent) (off-label use) (HHS [OI adult 2017]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary prophylaxis:</i> 50 or 75 mg once weekly in combination with dapsone and leucovorin calcium; <b>or</b> 25 mg once daily in combination with atovaquone and leucovorin calcium</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic maintenance (secondary prophylaxis):</i> 50 to 75 mg once weekly in combination with dapsone and leucovorin calcium; <b>or</b> 25 mg once daily in combination with atovaquone and leucovorin calcium</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Toxoplasmosis treatment: </b> Oral: 50 to 75 mg/day for 1 to 3 weeks depending on patient's tolerance and response, then may reduce dose by 50% and continue for 4 to 5 weeks; use with a sulfonamide in combination with leucovorin calcium</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Toxoplasmosis in HIV-infected patients (off-label) (HHS [OI adult 2017]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary prophylaxis (alternative agent):</i> 50 or 75 mg once weekly in combination with dapsone and leucovorin calcium; <b>or</b> 25 mg once daily in combination with atovaquone and leucovorin calcium</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic maintenance therapy (secondary prophylaxis):</i> 25 to 50 mg once daily in combination with sulfadiazine and leucovorin calcium; <b>or</b> 25 to 50 mg once daily in combination with clindamycin and leucovorin calcium (alternative regimen); <b>or</b> 25 mg once daily in combination with atovaquone and leucovorin calcium (alternative regimen)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment of Toxoplasma gondii encephalitis:</i> 200 mg as a single dose, followed by 50 mg (&lt;60 kg) or 75 mg (&ge;60 kg) daily, in combination with sulfadiazine and leucovorin calcium for at least 6 weeks; <b>or</b> 200 mg as a single dose, followed by 50 mg (&lt;60 kg) or 75 mg (&ge;60 kg) daily in combination with leucovorin calcium plus clindamycin or atovaquone or azithromycin (alternative regimens). <b>Note:</b> Pyrimethamine is no longer available in retail pharmacies in the US and is only available through a special pharmacy program. According to the HHS Guidelines for the prevention and treatment of opportunistic infections in the HIV-infected adults and adolescents, if there is a delay in procuring pyrimethamine for patients with suspected or documented toxoplasmosis who do not have a history of sulfa allergy, trimethoprim-sulfamethoxazole should be used in place of pyrimethamine-containing regimens until pyrimethamine is available.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216114\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pyrimethamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pyrimethamine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Isosporiasis (<i>Isospora belli</i> infection) in HIV-infected patients (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Pneumocystis</i> pneumonia (PCP) in HIV-infected patients (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Toxoplasmosis treatment: </b> Oral: Loading dose: 1 mg/kg/day divided into 2 equal daily doses for 2 to 4 days, then may decrease dose to 0.5 mg/kg/day divided into 2 doses for 4 weeks; use with a sulfonamide and leucovorin calcium</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Toxoplasmosis in HIV-infected patients (off-label):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary prophylaxis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: 1 mg/kg/day (or 15 mg/m<sup>2</sup>) once daily (maximum: 25 mg), with dapsone or atovaquone, in combination with leucovorin calcium (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic maintenance therapy (secondary prophylaxis):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: 1 mg/kg/day (or 15 mg/m<sup>2</sup>) once daily (maximum: 25 mg) given with sulfadiazine (or atovaquone or clindamycin), in combination with leucovorin calcium (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment of congenital toxoplasmosis:</i> Infants and Children: Loading dose: 2 mg/kg/day once daily for 2 days, then 1 mg/kg/day once daily for 2 to 6 months, followed by 1 mg/kg administered 3 times weekly, in combination with leucovorin calcium and sulfadiazine or clindamycin (treatment duration: 12 months) (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment of acquired toxoplasmosis:</i> Infants and Children: Acute induction: Loading dose: 2 mg/kg once daily (maximum: 50 mg/day) for 3 days, then 1 mg/kg/day once daily (maximum: 25 mg/day), with sulfadiazine or clindamycin in combination with leucovorin calcium. Continue acute induction therapy for &ge;6 weeks, then follow with chronic suppressive therapy (HHS [OI pediatric 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment of Toxoplasma gondii encephalitis:</i> Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216099\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22548579\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22548580\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216067\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Daraprim: 25 mg [scored]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216052\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26974540\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Daraprim: 25 mg [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45511770\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">As of June 2015, pyrimethamine is no longer available in retail pharmacies in the United States. It is available through a special pharmacy program (http://www.daraprimdirect.com/healthcare-providers).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alternate availability information for a compounded formulation may be found at http://www.hivma.org/Pyrimethamine_Alternatives/.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216070\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with meals to minimize GI distress.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216068\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Toxoplasmosis:</b> Treatment of toxoplasmosis (in combination with a sulfonamide).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45511771\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Congenital toxoplasmosis; Isosporiasis (Isospora belli infection) in HIV-infected patients (adolescents and adults); Pneumocystis pneumonia (PCP) in HIV-infected patients (adolescents and adults); Toxoplasma gondii encephalitis (treatment/primary prophylaxis/chronic maintenance therapy) in HIV-infected patients (adolescents and adults); Toxoplasma gondii encephalitis (treatment/primary prophylaxis/chronic maintenance therapy) in HIV-infected patients (children)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216134\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Daraprim may be confused with Dantrium, Daranide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216059\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia (large doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema multiforme, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, glossitis (atrophic), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukopenia, megaloblastic anemia, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Eosinophilic pneumonitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216074\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pyrimethamine or any component of the formulation; megaloblastic anemia secondary to folate deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216056\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic: Megaloblastic anemia, leukopenia, thrombocytopenia, and pancytopenia have been reported; most commonly with high doses. Monitor CBC and platelets twice weekly in patients receiving high-dose therapy (eg, when used for toxoplasmosis treatment).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Folate deficiency: Use caution in patients with possible folate deficiency (eg, malabsorption syndrome, pregnancy, alcoholism).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; G6PD deficiency: Use with caution in patients with possible G6PD deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\t Leucovorin: Administer leucovorin to prevent hematologic complications due to pyrimethamine-induced folic acid deficiency state; continue leucovorin during therapy and for 1 week after therapy is discontinued (to account for long half-life of pyrimethamine) (HHS [OI pediatric, 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216123\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C9 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216061\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9841&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended.  See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Pyrimethamine may enhance the adverse/toxic effect of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylfolate: May diminish the therapeutic effect of Pyrimethamine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PEMEtrexed: Pyrimethamine may enhance the adverse/toxic effect of PEMEtrexed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Pyrimethamine may enhance the adverse/toxic effect of PRALAtrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proguanil: Pyrimethamine may enhance the adverse/toxic effect of Proguanil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltitrexed: Pyrimethamine may enhance the adverse/toxic effect of Raltitrexed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonamide Antibiotics: Pyrimethamine may enhance the adverse/toxic effect of Sulfonamide Antibiotics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: Pyrimethamine may enhance the adverse/toxic effect of Trimethoprim. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216063\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216078\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. If administered during pregnancy (ie, for toxoplasmosis), supplementation of folate is strongly recommended. Pregnancy should be avoided during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216079\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pyrimethamine enters breast milk and may result in significant systemic concentrations in breast-fed infants. The effect of concurrent therapy with sulfonamide or dapsone (frequently used with pyrimethamine as combination treatment) must be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9603935\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take with meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216065\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, including platelet counts twice weekly with high-dose therapy (eg, when used for toxoplasmosis treatment; frequency not defined for lower doses); hepatic and renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216055\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits parasitic dihydrofolate reductase, resulting in inhibition of vital tetrahydrofolic acid synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216073\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Adults: 2.9 L/kg; distributed to the kidneys, lung, liver, and spleen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 87% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 80 to 95 hours (White 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 2 to 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (16% to 32%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216077\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Daraprim Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $27,000.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F216080\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Daraprim (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CY, CZ, DE, EG, ES, ET, GB, GH, GM, GN, GR, GY, HK, IE, IL, IN, IQ, IR, JM, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, NE, NG, NL, NO, OM, PE, PL, QA, SA, SC, SD, SI, SL, SN, SR, SY, TN, TT, TW, TZ, UG, UY, YE, ZA, ZM, ZW);</li>\n      <li>Daraprin (BR);</li>\n      <li>Malocide (FR);</li>\n      <li>Malomin (BD);</li>\n      <li>Meta (LK);</li>\n      <li>Primet (ID);</li>\n      <li>Pyrison (BD);</li>\n      <li>Tindurin (BD, HU);</li>\n      <li>Toxopirin (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Akinyanju O, Goddell JC, and Ahmed I, &ldquo;Pyrimethamine Poisoning,&rdquo; <i>Br Med J</i>, 1973, 4(885):147-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chirgwin K, Hafner R, Leport C, et al. Randomized phasae II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 study, <i>Clin Infect Dis</i>. 2002;34(9):1243-1250.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrimethamine-drug-information/abstract-text/11941551/pubmed\" target=\"_blank\" id=\"11941551\">11941551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chute JP, Decker CF, and Cotelingam J, &ldquo;Severe Megaloblastic Anemia Complicating Pyrimethamine Therapy,&rdquo; <i>Ann Intern Med</i>, 1995, 122(11):884-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daraprim (pyrimethamine) [prescribing information]. New York, NY: Vyera Pharmaceuticals; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"DHHS.2013\"></a>DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>. Published November 2013. Accessed February 25, 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrimethamine-drug-information/abstract-text/DHHS.2013/pubmed\" target=\"_blank\" id=\"DHHS.2013\">DHHS.2013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Parasitic Infections,&rdquo; Med Lett Drugs Ther, 2002. Available at http://www.medicalletter.com/freedocs/parasitic.pdf8544792</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katlama C, De Wit S, O'Doherty E, et al, &ldquo;Pyrimethamine-Clindamycin vs Pyrimethamine-Sulfadiazine as Acute and Long-Term Therapy for Toxoplasmic Encephalitis in Patients With AIDS,&rdquo; <i>Clin Infect Dis</i>, 1996, 22(2):268-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrimethamine-drug-information/abstract-text/8838183/pubmed\" target=\"_blank\" id=\"8838183\">8838183</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips-Howard PA and West LJ, &ldquo;Serious Adverse Drug Reactions to Pyrimethamine-Sulfadoxine, Pyrimethamine-Dapsone, and to Amodiaquine in Britain,&rdquo; <i>J R Soc Med</i>, 1990, 83(2):82-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrimethamine-drug-information/abstract-text/2138674/pubmed\" target=\"_blank\" id=\"2138674\">2138674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Porter SB and Sande MA, &ldquo;Toxoplasmosis of the Central Nervous System in the Acquired Immunodeficiency Syndrome,&rdquo; <i>N Engl J Med</i>, 1992, 327(23):1643-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrimethamine-drug-information/abstract-text/1359410/pubmed\" target=\"_blank\" id=\"1359410\">1359410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torre D, Casari S, Speranza F, et al, &ldquo;Randomized Trial of Trimethoprim-Sulfamethoxazole Versus Pyrimethamine-Sulfadiazine for Therapy of Toxoplasmic Encephalitis in Patients With AIDS. Italian Collaborative Study Group,&rdquo; <i>Antimicrob Agents Chemother</i>, 1998, 42(6):1346-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrimethamine-drug-information/abstract-text/9624473/pubmed\" target=\"_blank\" id=\"9624473\">9624473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed June 5, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Voorhis WC, &ldquo;Therapy and Prophylaxis of Systemic Protozoan Infections,&rdquo; <i>Drugs</i>, 1990, 40(2):176-202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrimethamine-drug-information/abstract-text/2121456/pubmed\" target=\"_blank\" id=\"2121456\">2121456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White NJ, &ldquo;Clinical Pharmacokinetics of Antimalarial Drugs,&rdquo; <i>Clin Pharmacokinet</i>, 1985, 10(3):187-215.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pyrimethamine-drug-information/abstract-text/3893840/pubmed\" target=\"_blank\" id=\"3893840\">3893840</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, &ldquo;Guidelines for the Treatment of Malaria,&rdquo; 2010, World Health Organization, Geneva. Available at http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9841 Version 122.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F216093\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F216094\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F216127\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F216098\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F216114\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F216099\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22548579\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22548580\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F216067\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F216052\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F26974540\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F45511770\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F216070\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F216068\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F45511771\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F216134\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F216059\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F216074\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F216056\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F216123\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F216061\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F216063\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F216078\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F216079\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9603935\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F216065\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F216055\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F216073\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F216077\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F216080\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9841|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pyrimethamine-patient-drug-information\" class=\"drug drug_patient\">Pyrimethamine: Patient drug information</a></li><li><a href=\"topic.htm?path=pyrimethamine-pediatric-drug-information\" class=\"drug drug_pediatric\">Pyrimethamine: Pediatric drug information</a></li></ul></div></div>","javascript":null}